Universities' Patent Policies Vary; Officials Say, 'Vive La Difference'

Marvin L. Speck was a professor of food science and microbiology at North Carolina State University when he developed a new process to help people digest milk. Speck recognized that his discovery, which he called SweetAcidophilus in honor of the fact that it improved on the unpleasant taste of the existing process, had commercial possibilities. So in 1972 he convinced the university to assign the trademark to a state dairy foundation, which then signed agreements with two companies, one to manuf

Written byBarbara Spector
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Marvin L. Speck was a professor of food science and microbiology at North Carolina State University when he developed a new process to help people digest milk. Speck recognized that his discovery, which he called SweetAcidophilus in honor of the fact that it improved on the unpleasant taste of the existing process, had commercial possibilities. So in 1972 he convinced the university to assign the trademark to a state dairy foundation, which then signed agreements with two companies, one to manufacture the necessary bacterium and another to market it.

But Speck’s sweet deal turned sour when he discovered he wouldn’t be making any money off his invention. He sued, but in 1984 the state Supreme Court upheld the university’s position that it owned the rights to the process.

That case taught university officials the dangers of an ambiguous policy on patent rights. Now NCSU faculty are required to sign a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies